when the program that yielded imatinib began, the understanding of the structure and function of protein kinases and the availability of medicinal chemical tools to modulate their activity were in ...

Figure 3: ABL kinase domain structure bound to imatinib, with locations of 13 resistance mutations indicated. Today, patients with CML are still treated with single-agent BCR-ABL kinase inhibitors ...